信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

III 信息服务

已收盘 05-11 16:00:00 EDT

4.14

+0.10

+2.48%

盘后4.14

+0.000.00%

18:43 EDT

最高4.16	最低3.93	成交量31.43万
今开4.05	昨收4.04	日振幅5.69%
总市值1.98亿	流通市值1.42亿	总股本4,788万
成交额128.68万	换手率0.92%	流通股本3,423万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"III","market":"US","secType":"STK","nameCN":"信息服务","latestPrice":4.14,"timestamp":1778529600000,"preClose":4.04,"halted":0,"volume":314252,"hourTrading":{"tag":"盘后","latestPrice":4.14,"preClose":4.14,"latestTime":"18:43 EDT","volume":1902,"amount":7874.5,"timestamp":1778539432536,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.024752475247524663,"floatShares":34233044,"shares":47884104,"eps":0.209971,"marketStatus":"已收盘","change":0.1,"latestTime":"05-11 16:00:00 EDT","open":4.05,"high":4.16,"low":3.93,"amount":1286812.916688,"amplitude":0.056931,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.209971,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1778572800000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1171256400000,"exchange":"NASDAQ","adjPreClose":4.04,"dividendRate":0.043478,"preHourTrading":{"tag":"盘前","latestPrice":4.13,"preClose":4.04,"latestTime":"08:53 EDT","volume":585,"amount":2386.789938,"timestamp":1778503994473,"change":0.09,"changeRate":0.022277,"amplitude":0.019802},"postHourTrading":{"tag":"盘后","latestPrice":4.14,"preClose":4.14,"latestTime":"18:43 EDT","volume":1902,"amount":7874.5,"timestamp":1778539432536,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.528789,"impliedVol":3.198,"impliedVolPercentile":0.9841},"requestUrl":"/m/hq/s/III","defaultTab":"news","newsList":[{"id":"2634476449","title":"港股异动 | 银诺医药-B(02591)午前涨超43% Suba的III期减重数据预计2026年年底前公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2634476449","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634476449?lang=zh_cn&edition=full","pubTime":"2026-05-11 11:37","pubTimestamp":1778470647,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，银诺医药-B午前涨超43%，截至发稿，涨42.21%，报17.99港元，成交额1.73亿港元。消息面上，银诺医药年度业绩显示，2025 年实现收入1.32亿元，亏损3.41亿元。值得注意的是，银诺医药基石投资者的禁售期将于2026年5月14日届满，相关股份将于5月15日正式解禁流通。Suba的III期减重数据预计2026年年底前公布。治疗肥胖及超重的III期临床研究，已于2025年完成患者入组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440054.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","BK4588","BK1161","VXUS","BK4585","III","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633182090","title":"翰宇药业(300199.SZ)：司美格鲁肽注射液减重及降糖两项国内适应症的III期临床试验均获得达到等效标准","url":"https://stock-news.laohu8.com/highlight/detail?id=2633182090","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633182090?lang=zh_cn&edition=full","pubTime":"2026-05-06 19:13","pubTimestamp":1778065991,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)发布公告，近日，公司司美格鲁肽注射液取得了III期临床数据，数据显示，该药物的减重及降糖两项国内适应症的III期临床试验均获得了达到等效标准。公司司美格鲁肽注射液在国内进行了两项临床试验，分别是：一项在二甲双胍单药治疗血糖控制不佳的2型糖尿病患者中比较HY310注射液与诺和泰®治疗32周的疗效和安全性的多中心、随机、开放设计的III期临床研究。一项在肥胖患者中比较HY310注射液与诺和盈®治疗44周的疗效和安全性的多中心、随机、开放设计的III期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438679.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300199","BK0070","BK4134","BK0239","III","BK0028","BK0077","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629896382","title":"港股异动 | 歌礼制药-B(01672)午前涨超4% 核心管线ASC30即将启动III期注册临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2629896382","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629896382?lang=zh_cn&edition=full","pubTime":"2026-04-24 11:10","pubTimestamp":1777000213,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，歌礼制药-B午前涨超4%，截至发稿，涨3.46%，报18.82港元，成交额2199.1万港元。消息面上，歌礼制药此前宣布启动ASC30_39FDC的临床开发，并计划于今年第三季度向美国FDA递交IND申请。口服剂型即将向FDA提交III期临床计划，公司预计将在2026年Q3正式启动。值得注意的是，智通财经APP在《歌礼制药-B：股价突破前高在即，场外资金为何选择观望？》中指出，礼来Orforglipron已于今年4月1日获FDA批准上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","BK1574","BK1515","III","VXUS","BK4588","BK4585","01672","01477","BK1191","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629096535","title":"康宁杰瑞制药-B(09966)：KN026新辅助治疗乳腺癌III期临床研究结果获选于2026 ASCO年会 LBA口头报告环节进行展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2629096535","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629096535?lang=zh_cn&edition=full","pubTime":"2026-04-22 12:03","pubTimestamp":1776830598,"startTime":"0","endTime":"0","summary":"KN026-004是一项随机、对照、开放、多中心III期临床研究，旨在评价KN026 联合HB1801±卡铂对比曲妥珠单抗联合帕妥珠单抗及多西他赛±卡铂在HER2阳性早期及局部晚期BC新辅助治疗中的疗效和安全性。KN026联合疗法有望成为HER2阳性早期及局部晚期BC新辅助治疗的全新标准疗法。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","BK1161","09966","BK1574","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628749960","title":"石药集团(01093)：注射用西罗莫司(白蛋白结合型)(HB1901)用于治疗晚期恶性血管周围上皮样细胞瘤(PEComa)的Ib / III期临床研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2628749960","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628749960?lang=zh_cn&edition=full","pubTime":"2026-04-20 17:51","pubTimestamp":1776678667,"startTime":"0","endTime":"0","summary":"HB1901表现出优异疗效，有望填补国内该适应症治疗空白，成为国内晚期恶性PEComa首款标准治疗方案。约50 %的恶性PEComa患者确诊时已属晚期，此时常合并转移，预后差。HB1901 -004是一项旨在评价注射用西罗莫司在晚期恶性PEComa患者中安全性与有效性的Ib / III期临床研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0880133367.SGD","LU0140636845.USD","LU1807302812.USD","LU1226287792.SGD","III","LU1960683339.HKD","BK1521","IE00B5MMRT66.SGD","IE00B031HY20.USD","IE00B543WZ88.USD","LU1993786604.SGD","BK1191","BK4134","LU1226288253.USD","BK1515","IE00BZ08YS42.EUR","IE0008368742.USD","LU0072913022.USD","LU0315179316.USD","LU0314109678.HKD","LU0326950275.SGD","LU1152091754.HKD","SG9999004220.SGD","LU0067412154.USD","01093","IE00BZ08YR35.GBP","LU1226288170.HKD","HK0000165453.HKD","LU0501845795.SGD","IE0008369823.USD","LU1152091168.USD","LU1008478684.HKD","LU1813983027.USD","IE00BZ08YT58.USD","LU1226287529.USD","LU2039709279.SGD","LU1951186391.HKD","LU1328277881.USD","LU1226287875.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628615057","title":"轩竹生物-B(02575)：地罗阿克一线治疗ALK阳性晚期非小细胞肺癌III期临床研究数据于2026年AACR展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2628615057","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628615057?lang=zh_cn&edition=full","pubTime":"2026-04-19 18:17","pubTimestamp":1776593868,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B 发布公告，集团已在2026年4月17日至2026年4月22日举行的2026年美国癌症研究协会年会以口头报告的形式展示地罗阿克一线治疗间变性淋巴瘤激酶阳性晚期非小细胞肺癌的临床III期研究结果。DIAMOND-2研究是一项在中国境内开展的多中心、随机、开放标签的III期临床研究，以克唑替尼作为对照，旨在头对头评估地罗阿克相较克唑替尼在一线治疗ALK阳性晚期NSCLC患者的有效性与安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430365.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02575","BK4134","BK1191","ALK","BK4588","BK4585","III","BK4008","BK4500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628227042","title":"药捷安康-B(02617)：替恩戈替尼单药治疗晚期胆管癌患者确证性III期临床完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2628227042","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628227042?lang=zh_cn&edition=full","pubTime":"2026-04-17 18:41","pubTimestamp":1776422489,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B(02617)公布，公司核心产品替恩戈替尼(Tinengotinib, TT-00420)单药治疗晚期胆管癌患者的确证性III期临床研究，于近日完成首例患者给药。本试验为在中国开展的一项评价替恩戈替尼对比化疗用于既往经一线系统性治疗后复发或进展的、携带FGFR2融合╱重排或突变的、手术不可切除的晚期或转移性肝内胆管癌患者的疗效与安全性的随机对照、开放、多中心III期临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430049.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","02617","BK1161","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627407539","title":"中国生物制药(01177)：维特柯妥拜单抗“CLDN18.2 ADC”一线胃及胃食管交界部腺癌III期临床试验完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2627407539","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627407539?lang=zh_cn&edition=full","pubTime":"2026-04-15 17:02","pubTimestamp":1776243779,"startTime":"0","endTime":"0","summary":"本研究为LM-302开展的第二项Ⅲ期临床试验，也是全球首个CLDN18.2 ADC药物采用无化疗方案用于胃癌一线治疗的Ⅲ期临床试验。这种“ADC+免疫”联合策略有望为CLDN18.2阳性胃癌患者带来更深度的肿瘤缓解。除本次启动的LM-302联合疗法用于一线治疗CLDN18.2阳性GC/GEJ的III期临床外，LM-302单药用于三线及以上CLDN18.2阳性GC/GEJ的III期临床研究已完成全部受试者入组。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428818.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","BK4080","BK4134","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1589","01177","BK4231","III","BK1515","ADC","BK1521","IE00BZ08YS42.EUR","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627473918","title":"来凯医药-B(02105)：LAE 002(Afuresertib)III期临床试验(AFFIRM-205)达到无进展生存期(PFS)的主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2627473918","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627473918?lang=zh_cn&edition=full","pubTime":"2026-04-15 08:22","pubTimestamp":1776212528,"startTime":"0","endTime":"0","summary":"II期临床试验是一项多中心、随机、双盲、安慰剂对照的关键性研究，旨在评估该联合疗法的抗肿瘤疗效及安全性。.每日一次口服LAE 002的治疗，患者耐受性良好，因不良事件而中止治疗的比例极低。本集团有权就许可区域内LAE 002的未来净销售额收取梯度销售分成，分成比率在十余个百分点至二十余个百分点。本集团计划在中国以外地区寻求战略合作伙伴，以加速LAE 002在国际市场的开发及商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4195","BK4134","02105","BK1161","BK4211","III","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627427789","title":"轩竹生物-B(02575)：安奈拉唑钠新适应症获批开展III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2627427789","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627427789?lang=zh_cn&edition=full","pubTime":"2026-04-15 06:34","pubTimestamp":1776206064,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B 发布公告，本集团自主研发的创新药安奈拉唑钠肠溶片近日获得中国国家药品监督管理局药品审评中心批准，开展含安奈拉唑钠肠溶片的铋剂四联疗法根除幽门螺杆菌的III期临床研究。本次安奈拉唑钠新适应症III期临床试验申请获批，有助于拓展产品适应症范围，提升本公司在消化疾病治疗领域的影响力，对本公司长远发展及商业化布局具有重要意义。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428565.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK1191","BK4134","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627498112","title":"港股异动 | 再鼎医药(09688)涨超3% 近日与安进达成全球临床合作 Zoci正处于全球注册性临床III期阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2627498112","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627498112?lang=zh_cn&edition=full","pubTime":"2026-04-14 09:46","pubTimestamp":1776131184,"startTime":"0","endTime":"0","summary":"消息面上，近日，再鼎医药官微宣布，公司与安进公司达成一项全球临床研究合作，旨在评估再鼎医药处于临床阶段的靶向delta样配体3的抗体药物偶联物zocilurtatug pelitecan联合安进IMDELLTRA，一款靶向DLL3的双特异性T细胞衔接器疗法，用于治疗广泛期小细胞肺癌患者。作为该合作协议的一部分，安进将申办一项全球1b期研究，评估zoci联合IMDELLTRA在ES-SCLC患者中的安全性和有效性。再鼎医药将保留zoci的完整所有权，并将向安进提供临床研究用药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B2B36J28.USD","SG9999001440.SGD","LU2112291526.USD","LU2468319806.SGD","AMGN","LU0058720904.USD","BK4548","LU2488822045.USD","LU1983299246.USD","BK1574","IE0009355771.USD","BK4533","09688","BK4534","BK1588","LU0320765992.SGD","LU1023059063.AUD","LU1061106388.HKD","BK4526","BK4566","BK4134","IE00BJJMRZ35.SGD","ZLAB","BK1161","VXUS","IE00B4R5TH58.HKD","BK4581","LU0109394709.USD","LU1571399168.USD","LU0289739699.SGD","BK4588","BK4599","LU0868494617.USD","IE00BJT1NW94.SGD","LU2089984988.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","BK4139","LU2242646821.SGD","BK4585","III","LU1057294990.SGD","LU0122379950.USD","BK4531","LU2242652126.USD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627481537","title":"港股异动 | 科笛-B(02487)涨超3%  CU-20101（注射用A型肉毒毒素）完成中国III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2627481537","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627481537?lang=zh_cn&edition=full","pubTime":"2026-04-13 13:37","pubTimestamp":1776058657,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科笛-B(02487)涨超3%，截至发稿，涨3.25%，报4.76港元，成交额40.99万港元。消息面上，科笛今日宣布，集团完成CU-20101（注射用A型肉毒毒素）用于改善中度至重度眉间纹的中国III期临床试验。该临床试验旨在评估CU-20101单次及重复注射治疗中重度眉间纹的有效性和安全性。该临床试验以参比制剂保妥适®注射用A型肉毒毒素（“BOTOX®”）作为对照。该临床试验于2025年11月完成所有受试者出组，并于2026年1月完成数据库锁定且取得积极的顶线结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427621.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4588","BK4585","02487","VXUS","BK4134","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627102514","title":"科笛-B(02487)：CU-20101(注射用A型肉毒毒素)用于改善中度至重度眉间纹完成中国III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2627102514","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627102514?lang=zh_cn&edition=full","pubTime":"2026-04-13 08:18","pubTimestamp":1776039501,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科笛-B 发布公告，本集团完成CU-20101用于改善中度至重度眉间纹的中国III期临床试验。在安全性方面，CU-20101的整体安全性良好，未发生导致提前煺出试验或导致死亡的不良事件，且未发生治疗有关的严重不良事件。CU-20101与BOTOX的安全性评估情况相近，未出现新的安全性信号。CU-20101多次重复注射给药后的有效性及安全性表现与单次用药相似。CU-20101将进一步丰富本集团的皮肤产品矩阵，并有利于与本集团现有产品形成协同效应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427503.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK4134","BK1161","02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626975845","title":"开山股份(300257.SZ)肯尼亚Menengai III 35兆瓦地热电站投入商业运营","url":"https://stock-news.laohu8.com/highlight/detail?id=2626975845","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626975845?lang=zh_cn&edition=full","pubTime":"2026-04-09 07:54","pubTimestamp":1775692490,"startTime":"0","endTime":"0","summary":"智通财经APP讯，开山股份(300257.SZ)公告，公司下属公司Orpower Twenty Two Limited公司(简称“Orpower22”)顺利完成了肯尼亚Menengai III 35兆瓦地热电站的可靠性测试，该电站机组调试、测试工作已圆满结束。Menengai III 35兆瓦地热电站已于2026年3月10日正式投入商业运营。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426300.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","BK0259","300257","BK0070","BK0188","BK0196","BK0117","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624562436","title":"港股异动 | 欧康维视生物-B(01477)午后涨超16% OT-211治疗干眼症III期临床试验完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2624562436","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624562436?lang=zh_cn&edition=full","pubTime":"2026-04-01 14:26","pubTimestamp":1775024786,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，欧康维视生物-B午后涨超16%，截至发稿，涨15.33%，报8.5港元，成交额2606.87万港元。消息面上，欧康维视生物发布公告称，OT-211在中国开展的III期临床试验已完成首例患者入组。首例患者成功入组标志着OT-211在中国的临床开发取得重要里程碑进展，并体现了集团致力于为DED患者推进创新疗法。公开资料显示，Alcon Inc.开发出AR-15512的0.003%浓度滴眼液配方，并完成一项IIb期及三项III期临床试验。OT-211已于2025年5月28日获FDA批准用于治疗DED的体征及症状。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423857.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK4134","BK1574","BK4585","BK4588","III","VXUS","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623583940","title":"康宁杰瑞制药-B(09966)：KN026新辅助治疗HER2阳性乳腺癌III期临床研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2623583940","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623583940?lang=zh_cn&edition=full","pubTime":"2026-03-31 19:03","pubTimestamp":1774955020,"startTime":"0","endTime":"0","summary":"BC是中国女性发病率最高的恶性肿瘤，其中HER2阳性亚型约占20%至30%。该研究旨在比较KN026联合HB1801±卡铂对比曲妥珠单抗联合帕妥珠单抗和多西他赛±卡铂新辅助治疗早期和局部晚期HER2阳性BC的有效性及安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423118.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK1574","BK1161","BK4134","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623347904","title":"宜明昂科-B(01541)：IMM0306治疗复发性╱难治性滤泡性淋巴瘤的III期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2623347904","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623347904?lang=zh_cn&edition=full","pubTime":"2026-03-31 00:28","pubTimestamp":1774888085,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B 发布公告，IMM0306联合来那度胺治疗复发性╱难治性滤泡性淋巴瘤的III期临床试验顺利完成首例患者给药。由本集团独立研发的IMM0306是一种靶向分化簇47 及分化簇20 的双特异性分子，是全球首个进入临床阶段的CD47和CD20双靶向双特异性分子。截至本公告日期，本集团拥有IMM0306的全球知识产权及商业化权利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422402.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","III","BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623346987","title":"欧康维视生物-B(01477)：OT-211 III期临床试验完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2623346987","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623346987?lang=zh_cn&edition=full","pubTime":"2026-03-30 22:05","pubTimestamp":1774879506,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B 发布公告，OT-211 在中国开展的III期临床试验已完成首例患者入组。OT-211 为一种 0.003%浓度滴眼液配方，亦为首款获美国食品药品监督管理局批准用于治疗干眼症的TRPM8激动剂。首例患者成功入组标志着OT-211在中国的临床开发取得重要里程碑进展，并体现了集团致力于为DED患者推进创新疗法。OT-211 已于2025年5月 28日获FDA批准用于治疗DED的体征及症状。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK1574","01477","BK4134","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622830947","title":"益方生物(688382.SH)：D-2570治疗银屑病注册性III期临床试验完成全部受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2622830947","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622830947?lang=zh_cn&edition=full","pubTime":"2026-03-26 16:48","pubTimestamp":1774514885,"startTime":"0","endTime":"0","summary":"智通财经APP讯，益方生物(688382.SH)公告，公司自主研发的TYK2抑制剂D-2570用于治疗中重度斑块状银屑病(PsO)的注册性III期临床试验已于近日完成全部受试者入组。公告显示，D-2570是公司自主研发的一款靶向酪氨酸激酶2(TYK2)的新型口服选择性抑制剂，用于治疗银屑病等自身免疫性疾病。D-2570通过选择性结合TYK2假激酶域JH2部位，抑制TYK2激酶的活性，进而阻断TYK2依赖性的细胞因子信号传导介导的STAT蛋白的磷酸化，抑制炎症因子释放，参与免疫调节。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","BK0239","688382","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622881272","title":"港股异动 | 轩竹生物-B(02575)早盘涨超18% 吡洛西利III期BRIGHT-2临床研究结果于国际医学顶刊发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2622881272","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622881272?lang=zh_cn&edition=full","pubTime":"2026-03-26 09:47","pubTimestamp":1774489669,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，轩竹生物-B早盘涨超18%，截至发稿，涨11.85%，报40.58港元，成交额1886.4万港元。消息面上，3月24日，轩竹生物-B发布公告，公司自主研发的新型CDK2/4/6抑制剂吡洛西利的III期BRIGHT-2临床研究最终分析结果，已于近日在国际顶尖医学期刊《美国医学会杂志·肿瘤学》正式在线全文发表。公司曾于2025年4月在《Nature Communications》期刊上公布BRIGHT-2研究的中期分析结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419250.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0181","BK4134","000516","BK4585","02575","BK0188","BK0077","BK4588","BK0236","III","BK0114","BK1191","BK0046","BK0096","VXUS","BK0146","BK0042"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.isg-one.com","stockEarnings":[{"period":"1week","weight":-0.017},{"period":"1month","weight":-0.0074},{"period":"3month","weight":-0.229},{"period":"6month","weight":-0.2305},{"period":"1year","weight":0.01},{"period":"ytd","weight":-0.301}],"compareEarnings":[{"period":"1week","weight":0.0235},{"period":"1month","weight":0.0911},{"period":"3month","weight":0.0681},{"period":"6month","weight":0.0993},{"period":"1year","weight":0.3054},{"period":"ytd","weight":0.0817}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Information Services Group, Inc.于2006年7月20日在特拉华州注册成立。该公司是一家全球领先的技术研究和咨询公司。ISG是超过900家客户、超过75家百强企业值得信赖的商业伙伴，致力于帮助企业、公共部门组织以及服务和技术提供商实现卓越运营和更快增长。该公司专门从事数字化转型服务，包括自动化、云和数据分析；采购咨询；托管治理和风险服务；网络载体服务；技术战略和运营设计；变革管理；市场情报和技术研究与分析。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.022101},{"month":2,"riseRate":0.5,"avgChangeRate":0.004642},{"month":3,"riseRate":0.315789,"avgChangeRate":0.030463},{"month":4,"riseRate":0.473684,"avgChangeRate":-0.00444},{"month":5,"riseRate":0.315789,"avgChangeRate":-0.027588},{"month":6,"riseRate":0.5,"avgChangeRate":0.015439},{"month":7,"riseRate":0.444444,"avgChangeRate":0.01427},{"month":8,"riseRate":0.555556,"avgChangeRate":0.010481},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.004212},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.036611},{"month":11,"riseRate":0.611111,"avgChangeRate":0.053419},{"month":12,"riseRate":0.555556,"avgChangeRate":0.003262}],"exchange":"NASDAQ","name":"信息服务","nameEN":"Information"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信息服务,III,信息服务股票,信息服务股票老虎,信息服务股票老虎国际,信息服务行情,信息服务股票行情,信息服务股价,信息服务股市,信息服务股票价格,信息服务股票交易,信息服务股票购买,信息服务股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}